BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pegenzileukin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pegenzileukin\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04643002-3355@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Pegenzileukin: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Pegenzileukin\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuxima
 b in Combination With Novel Agents in RRMM - Master Protocol\nEstimated pr
 imary completion: 13 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pegenzileukin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/pegenzileukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
